Advertisement

Topics

Latest "Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations" News Stories

05:01 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations" found in our extensive news archives from over 250 global news sources.

More Information about Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations for you to read. Along with our medical data and news we also list Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations Clinical Trials, which are updated daily. BioPortfolio also has a large database of Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations Companies for you to search.

Showing "Tobacco Treatment Outreach Reduce Disparities Primary Care Populations" News Articles 1–25 of 33,000+

Wednesday 20th March 2019

Mundipharma Announces Launch of INVOKANA® and VOKANAMET® in Norway for the Treatment of Type 2 Diabetes as Part of Exclusive Distribution Agreement with Janssen

Invokana® and Vokanamet® are now available across the whole of Scandinavia, and in a total of 18 markets across Europe There is a significant patient need for new and effective diabetes treatment options, as the number of people with the condition in Europe is predicted to rise to 67 million by 20451 ...


Kensington Natural Smiles Announces New Hybrid-Responsive Website

Kensington Natural Smiles in Kensington, MD, is pleased to announce the release of its new Hybrid-Responsive™ website: https://www.susanhodds.com. KENSINGTON, Md. (PRWEB) March 20, 2019 Kensington Natural Smiles in Kensington, MD, is pleased to announce the release of its new Hybrid-Responsive™ website: https://www.susanhodds.com. According to Dr. Susan Ho, the dentist at Kensington Natural S...

I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

SHANGHAI, March 20, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, and German biopharma company MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR), today announced that the first pat...


Tuesday 19th March 2019

Royal Holloway professors to lead new to research into curing Neurofibromatosis type 1

Linda Popplewell, Lecturer in Biomedical Sciences, and world-renowned Professor George Dickson, from the School of Biological Sciences, both at Royal Holloway, will lead a team looking for a treatment for NF1, a genetic disorder that causes tumors to form on nerve tissue.

Major scientific study of wound care dressings wins 'Best Clinical or Preclinical Research Award'

UNIVERSITY of Huddersfield researchers have taken part in an award-winning project that will enable healthcare companies to develop and supply more effective wound dressings.

New study aims to reduce online sexual exploitation of children

On March 26th, the Karolinska Institutet and Karolinska University Hospital in Swedenare launching a new study aimed at reducing online sexual exploitation of children. Recruitment of study participants will take place in forums on the encrypted part of the internet called the darknet.

[Personal View] Challenges and opportunities for the management of infectious diseases in Europes' prisons: evidence-based guidance

People in prison have multiple complex health and social care needs. These are likely to be the result of a combination of overlapping, and sometimes interlinked, risk factors for infection, ill-health, and incarceration, such as problem drug use. Incarceration can represent a unique opportunity to make high-quality health care available to people in prison and to target socially deprived groups w...

Pregnancy, psychiatry and IBD: multidisciplinary care is crucial

Raynauds Disease Treatment Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Raynauds Disease Treatment report provides an independent information about the Raynauds Disease Treatment industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent...

Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH

NEW YORK and LONDON, March 20, 2019 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (the "Company", "Tiziana Life Sciences" or "Tiziana") (NASDAQ: TLSA; AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology and immunology, today announced that it has submitted* an Investigational New Drug application ("...

Does alcohol consumption have an effect on arthritis?

(Wiley) Several previous studies have demonstrated that moderate alcohol consumption is linked with less severe disease and better quality of life in patients with rheumatoid arthritis, but a new Arthritis Care & Research study suggests that this might not be because drinking alcohol is beneficial.

Disease burden in osteoarthritis is similar to rheumatoid arthritis

(Wiley) Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment. A new study in Arthritis & Rheumatology indicates that OA and RA have similar impacts or burdens on patients when they first visit rheumatologists, howev...

First ratings for youth football helmets address sport's largest pool of athletes

(Virginia Tech) With the release of youth football-helmet ratings by the Virginia Tech Helmet Lab -- already renowned for their helmet ratings for varsity football and other sports -- consumers can see which helmets best reduce concussion risk.

The recent spread of coyotes across North America did not doom deer populations

(North Carolina Museum of Natural Sciences) Coyotes eat deer, but not enough to limit the deer population at a large scale. A new study of deer numbers across the eastern United States has found that the arrival and establishment of coyote predators has not caused the number of deer harvested by hunters to decline.

Study reveals that coyotes are not controlling deer populations in eastern US states

(Wiley) Coyotes expanded their range to colonize eastern North America over the last century, where their impacts on white-tailed deer populations are highly debated. In a Journal of Wildlife Management study, researchers conducted the first long-term, large scale assessment and documented no consistent decline in deer harvest numbers after coyote arrival.

Blood test could predict kidney transplant rejection

UK researchers have found a way to predict rejection of a kidney transplant before it happens, by monitoring the immune system of transplant patients. Their research has been published in the journal EBioMedicine. A renal transplant offers the best treatment for patients whose kidneys have failed, with around 3000 carried out annually in the UK. Acute rejection occurs when the body’s immune sys...

Using optogenetics, scientists at @scrippsresearch switch off addiction-like behaviors and reduce physical withdrawal symptoms in alcohol-dependent rats: http://ow.ly/PPTi30o6z68 

Using optogenetics, scientists at @scrippsresearch switch off addiction-like behaviors and reduce physical withdrawal symptoms in alcohol-dependent rats: http://ow.ly/PPTi30o6z68 

Sage Therapeutics' Zulresso becomes first treatment for post-partum depression approved in US https://firstwordpharma.com/node/1630548?tsid=28®ion_id=6 …

Sage Therapeutics' Zulresso becomes first treatment for post-partum depression approved in US https://firstwordpharma.com/node/1630548?tsid=28&region_id=6 …

Zulresso Is Sage’s First Step In Postpartum Depression Treatment

I.V. Zulresso is the first US FDA-approved drug for postpartum depression (PPD) and Sage's first commercial product – with a...   

Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression

Approval based on results from three pivotal trials showing treatment with ZULRESSO provided significant and rapid reduction of depressive symptoms within days Postpartum depression is the most common medical complication of childbirth, estimated to affect approximately 400,000 women annually in the U.S. Sage Therapeutics (NASDAQ: SAGE)...

Stanford Opens Institute for Human-Centered Artificial Intelligence

Stanford University, announced it is opening the Stanford Institute for Human-Centered Artificial Intelligence (HAI) with the mission to to advance artificial intelligence (AI) research, education, policy, and practice to improve the human condition. The institute will work closely with companies across sectors, including technology, financial services, health care and manufacturing, to create a ...

Prescriptions for healthy food might save lives - and money

(Reuters Health) - Healthy food prescriptions written for Medicare and Medicaid beneficiaries might lower the risk of costly chronic illnesses, such as diabetes and cardiovascular disease, and at the same time lower the costs of care, a new study sug...

MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study 19.03.2019 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, and Shanghai, China, March 19, 2019   MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma   MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX...

'Transformative': FDA approves first drug for postpartum depression

The treatment is delivered through a one-time, 60-hour intravenous infusion that may improve symptoms within 24 hours.

LTC Senior Management to Participate in the Jefferies 2019 Global Healthcare REIT Summit

LTC Properties Inc. (NYSE: LTC), a real estate investment trust that invests in seniors housing and health care properties, today announced that senior management will participate in the Jefferies 2019 Global Healthcare REIT Summit in New York on April 2, 2019. The Company’s presentation package will be available on the Company’s website at ww...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks